GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Asset Turnover

Nymox Pharmaceutical (Nymox Pharmaceutical) Asset Turnover : 0.00 (As of Sep. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Nymox Pharmaceutical's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Nymox Pharmaceutical's Total Assets for the quarter that ended in Sep. 2023 was $0.47 Mil. Therefore, Nymox Pharmaceutical's Asset Turnover for the quarter that ended in Sep. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Nymox Pharmaceutical's annualized ROE % for the quarter that ended in Sep. 2023 was 173.43%. It is also linked to ROA % through Du Pont Formula. Nymox Pharmaceutical's annualized ROA % for the quarter that ended in Sep. 2023 was -881.70%.


Nymox Pharmaceutical Asset Turnover Historical Data

The historical data trend for Nymox Pharmaceutical's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Asset Turnover Chart

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.02 - - -

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nymox Pharmaceutical's Asset Turnover

For the Biotechnology subindustry, Nymox Pharmaceutical's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Asset Turnover falls into.



Nymox Pharmaceutical Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Nymox Pharmaceutical's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0/( (1.443+1.625)/ 2 )
=0/1.534
=0.00

Nymox Pharmaceutical's Asset Turnover for the quarter that ended in Sep. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=0/( (0.271+0.669)/ 2 )
=0/0.47
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Nymox Pharmaceutical  (OTCPK:NYMXF) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Nymox Pharmaceutical's annulized ROE % for the quarter that ended in Sep. 2023 is

ROE %**(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-4.144/-2.3895
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4.144 / 0)*(0 / 0.47)*(0.47/ -2.3895)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-0.1967
=ROA %*Equity Multiplier
=-881.70 %*-0.1967
=173.43 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Nymox Pharmaceutical's annulized ROA % for the quarter that ended in Sep. 2023 is

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=-4.144/0.47
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-4.144 / 0)*(0 / 0.47)
=Net Margin %*Asset Turnover
= %*0
=-881.70 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Nymox Pharmaceutical Asset Turnover Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

By GuruFocusNews GuruFocusNews 11-15-2021

Nymox Announces $2 Million Private Placement

By Marketwired 08-02-2023

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 07-02-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-02-2022

May 2023 Market Cap Requirement Update

By GlobeNewswire GlobeNewswire 11-25-2022

NYMOX Receives Deficiency Letter from NASDAQ

By PurpleRose PurpleRose 07-14-2022

Nymox Announces $5 Million Registered Direct Offering

By GuruFocusNews GuruFocusNews 03-18-2022

Nymox Shareholder Update

By GuruFocusNews GuruFocusNews 12-13-2021